CSPC Megalith Biopharmaceutical Technology

CSPC Megalith Biopharmaceutical Technology is a clinical-stage biotechnology subsidiary of CSPC Pharmaceutical Group, focused on the discovery and development of innovative biologics. The company maintains a robust pipeline centered on high-growth therapeutic areas, particularly oncology and infectious diseases, utilizing proprietary platforms for antibody-drug conjugates (ADCs) and mRNA-based therapeutics. Megalith achieved a significant milestone by developing China's first domestically produced mRNA COVID-19 vaccine to receive emergency use authorization. Several of its lead oncology assets, including SYSA1801 and SYS6002, have been out-licensed to international partners for global clinical development. The company operates as the primary innovation engine for biologics within the broader CSPC Pharmaceutical ecosystem.